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Background 
• 2012 ACR Guidelines recommend 
biologic switching if there is evidence of 
high/moderate disease activity1. 
• High disease activity is defined as 
DAS28 of >5.1.  
• US is recognised as a powerful tool to 
detect inflammatory changes when 
compared to clinical examination, and is 
effective for assessing response to 
treatment2.  
 
Aims 
We aim to establish the role of US in 
biologic switching when compared to 
clinical assessment with DAS28 and HAQ 
in patients with Rheumatoid Arthritis. 
 
We aim to show that confirmation of 
ultrasound synovitis in patients with 
biologic failure, influences consultant 
decision to switch to a different drug. 
  
Methods 
• Twenty patients with suspected biologic 
failure referred for Musculoskeletal US 
from two secondary care centers in the 
North East of England.  
• Standardised inclusion (on biologics 
min 6 months) and exclusion criteria 
(NSAIDS within 48 hours, Steroids 
within 2 weeks) 
• PRF 0.6-0.8 for all images 
• US of the Backhaus 7 joint count was 
performed on the most affected side.  
• OMERACT semi-quantitive scoring was 
used to assess grey scale, power 
doppler and tenosynovitis.  
• A total ultrasound score (TUSS) was 
derived from the sum of these scores.  
• DAS28 and HAQ were obtained prior to 
biologic treatment and at the time of 
US.  
• Physician decision to continue or switch 
biologic was documented pre- and 
post-US. 
 
Results 
• Male: Female ratio was 1:3 (consistent 
with UK national demographics for 
incidence of RA) 
• Age range was 30-69 (mean 56.9).  
• 95% of patients were seropositive.  
• 80% were taking at least 1 conventional 
DMARD in addition to a biologic.  
• IQR for length of treatment on current 
biologic was 9.5 months to 4 years 2 
months. 
• Pre-Biologic DAS range 4.40 -8.24, 
Mean 6.23, IQR 5.77 – 6.70.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions 
• Overestimation of disease activity 
by DAS28 is most likely influenced 
by subjective measures.  
• Using DAS28 alone may result in 
misclassification of disease activity 
and over-treatment with 
subsequent high morbidity and 
financial costs. 
• Treatment escalation was more 
likely when US demonstrated 
synovitis, and less likely when US 
negative. 
• We plan to modify our biologic 
treatment pathway with the addition 
of MSK US assessment in order to 
ensure the provision of targeted 
therapy for those with suspected 
biologic failure. 
• Current lack of evidence for 
treating to US target has long term 
benefit over treating to DAS28 
target. More research needed. 
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• Pre-Biologic HAQ range 1.375-2.875, 
mean 1.984, IQR = 1.500-2.310.  
 
 
 
 
 
 
 
 
 
 
• No significant correlation between pre-
biologic DAS and HAQ (r=0.3783).  
• No significant correlation between 
DAS28 and HAQ at the time of US 
(r=0.3178). 
 
 
 
 
 
 
 
 
 
 
 
 
 
• No significant correlation between HAQ 
and TUSS (r=-0.673, p<0.01).  
• HAQ positively correlated with VAS 
(r=0.5436, p<0.05), however neither of 
these measures correlated with 
inflammatory markers or US scores.  
 
14/20 (70%) cases altered clinician 
opinion on treatment following US 
 
 
  
 
 
 
 
 
 
 
 
 
DAS28 at US 
Total Ultrasound 
Score (TUSS) 
Clinician 
Impression pre-US 
Clinician 
Impression post US 
High 
Activity 
(>5.1) 
11  
(55%) 
High 
Activity 
(>12) 
5 
(25%) 
High 
Activity 
4 
(20%) 
High 
Activity 
5 
(25%) 
Moderate 
Activity 
(3.2-5.1) 
6  
(30%) 
Moderate 
Activity   
(10-12) 
4 
(20%) 
Moderate 
Activity  
10 
(50%) 
Moderate 
Activity  
4 
(20%) 
Low 
Activity 
(<3.2) 
3  
(15%) 
Low 
Activity 
(<10) 
11 
(55%) Low Activity  
6 
(30%) Low Activity  
11 
(55%) 
0
2
4
6
8
10
12
Current cDMARDS 
Number
of
patients
0
1
2
3
4
5
6
7
8
DAS at US compared to HAQ 
at US 
DAS28
HAQ
0
10
20
30
2
.1
8
3
.0
4
4
.0
6
4
.4
1
5
.0
5
5
.3
2
5
.3
9
5
.5
6
.0
4
6
.8
1
To
ta
l U
S 
ac
ti
vi
ty
 s
co
re
 
DAS28 
DAS28 weakly correlates with 
total US activity score 
(r=0.3854, p<0.10) 
Table 1.  Disease Activity measured by DAS28 and Ultrasound,  and Clinical 
Outcomes 
